A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging

• Published in: The American journal of surgery Vol. 212; no. 4; pp. 700 - 714
• Main Authors: Lopez, Nicole E., M.D, Weiss, Anna C., M.D, Robles, Julie, B.S, Fanta, Paul, M.D, Ramamoorthy, Sonia L., M.D., M.S., F.A.C.S
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2016; Elsevier Limited
• Subjects: Biomarkers, Tumor - genetics; Cancer therapies; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Gene expression; Gene Expression Profiling - methods; Genetic assays; Genetic expression profiles; Genetic signatures; Genetic Testing - methods; Genomes; Genomics; Hospitals; Humans; Keywords; Medical prognosis; Metastasis; Mutation; Patients; Polymerase chain reaction; Stage II; Studies; Subject heading schemes; Surgery; Genetic assays; Genetic expression profiles; Stage II; Genetic signatures; Colorectal cancer
• ISSN: 0002-9610; 1879-1883
• DOI: 10.1016/j.amjsurg.2016.06.019

Abstract Background In recent years, increasingly accessible and novel genetic technologies have spurred keen interest in the application of cancer genetics in predicting prognosis and response to treatment. In particular, investigators have eagerly sought to establish and validate genetic signatures that might improve the identification of patients with stage II colorectal cancer (CRC) who are at highest risk of recurrence. To better understand the evidence for incorporation of genetic assays into clinical practice, we have systematically reviewed those assays that have been validated and are available for clinical use in stage II CRC. Methods A systematic review was performed using PubMed, Web of Science and Scopus databases. The GRADE system was used to evaluate level of evidence and strength of recommendations. Results After duplicates were removed and exclusion criteria were applied, there were 13 articles for review. Conclusion Identifying high-risk patients with stage II CRC using molecular profiling has been the primary aim of many investigators, and the approach is translating into clinical utility.